[go: up one dir, main page]

PL1926483T3 - Leczenie chorób autoimmunologicznych - Google Patents

Leczenie chorób autoimmunologicznych

Info

Publication number
PL1926483T3
PL1926483T3 PL06793341T PL06793341T PL1926483T3 PL 1926483 T3 PL1926483 T3 PL 1926483T3 PL 06793341 T PL06793341 T PL 06793341T PL 06793341 T PL06793341 T PL 06793341T PL 1926483 T3 PL1926483 T3 PL 1926483T3
Authority
PL
Poland
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
PL06793341T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1926483T3 publication Critical patent/PL1926483T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06793341T 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych PL1926483T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
EP06793341A EP1926483B1 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
PL1926483T3 true PL1926483T3 (pl) 2011-05-31

Family

ID=37056992

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10174280T PL2295049T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych
PL06793341T PL1926483T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10174280T PL2295049T3 (pl) 2005-09-09 2006-09-07 Leczenie chorób autoimmunologicznych

Country Status (28)

Country Link
US (1) US20080200438A1 (pl)
EP (2) EP2295049B1 (pl)
JP (4) JP5244598B2 (pl)
KR (3) KR20140117704A (pl)
CN (1) CN101257899B (pl)
AT (1) ATE489948T1 (pl)
AU (2) AU2006289100B2 (pl)
BR (1) BRPI0615906A2 (pl)
CA (2) CA2820510A1 (pl)
CY (1) CY1111285T1 (pl)
DE (1) DE602006018629D1 (pl)
DK (2) DK2295049T3 (pl)
ES (2) ES2357426T3 (pl)
IL (2) IL189665A (pl)
JO (1) JO2655B1 (pl)
MA (1) MA29787B1 (pl)
MX (1) MX2008003170A (pl)
NO (1) NO20081727L (pl)
NZ (2) NZ566137A (pl)
PL (2) PL2295049T3 (pl)
PT (2) PT1926483E (pl)
RU (2) RU2424795C2 (pl)
SG (1) SG165364A1 (pl)
SI (2) SI1926483T1 (pl)
TN (1) TNSN08103A1 (pl)
TW (2) TWI372620B (pl)
WO (1) WO2007028821A2 (pl)
ZA (1) ZA200801694B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
PT2511262T (pt) 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
BRPI0617077A2 (pt) * 2005-10-07 2015-01-06 Kyorin Seiyaku Kk Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574011A (en) * 2006-08-08 2011-10-28 Kyorin Seiyaku Kk Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
CA2659599C (en) * 2006-08-08 2014-06-17 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN102123735A (zh) * 2008-05-20 2011-07-13 杏林制药株式会社 诱导缓解维持剂
EP2328571B1 (en) * 2008-08-18 2014-06-18 Novartis AG Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives
KR20130066630A (ko) * 2010-05-06 2013-06-20 노파르티스 아게 자가면역 질환의 치료

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
CN1708293A (zh) * 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
CA2499977A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Edible solid composition and dosage form
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
NZ592339A (en) * 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
MXPA06002349A (es) * 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
US20090275553A1 (en) * 2004-11-29 2009-11-05 Kovarik John M Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2015025002A (ja) 2015-02-05
CN101257899A (zh) 2008-09-03
JP2017019854A (ja) 2017-01-26
CY1111285T1 (el) 2015-08-05
JO2655B1 (en) 2012-06-17
RU2011111117A (ru) 2012-09-27
NZ588372A (en) 2012-03-30
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
WO2007028821A2 (en) 2007-03-15
DE602006018629D1 (de) 2011-01-13
AU2006289100B2 (en) 2010-07-22
SG165364A1 (en) 2010-10-28
JP2009507810A (ja) 2009-02-26
ZA200801694B (en) 2009-09-30
IL189665A0 (en) 2008-06-05
IL233328A0 (en) 2014-08-31
ES2529724T3 (es) 2015-02-25
JP5244598B2 (ja) 2013-07-24
JP2013010802A (ja) 2013-01-17
BRPI0615906A2 (pt) 2011-05-31
KR20140117704A (ko) 2014-10-07
EP1926483A2 (en) 2008-06-04
EP2295049B1 (en) 2014-11-26
SI2295049T1 (sl) 2015-03-31
MA29787B1 (fr) 2008-09-01
RU2493840C2 (ru) 2013-09-27
HK1149906A1 (en) 2011-10-21
US20080200438A1 (en) 2008-08-21
DK1926483T3 (da) 2011-03-14
PT1926483E (pt) 2011-03-03
KR20140019033A (ko) 2014-02-13
EP2295049A1 (en) 2011-03-16
KR101476591B1 (ko) 2014-12-24
WO2007028821A3 (en) 2007-05-03
AU2010224355A1 (en) 2010-10-14
NZ566137A (en) 2011-05-27
ATE489948T1 (de) 2010-12-15
KR20080046231A (ko) 2008-05-26
RU2008113187A (ru) 2009-10-20
RU2424795C2 (ru) 2011-07-27
CA2620554C (en) 2013-12-17
ES2357426T3 (es) 2011-04-26
TWI372620B (en) 2012-09-21
TW201034659A (en) 2010-10-01
PL2295049T3 (pl) 2015-04-30
AU2010224355B2 (en) 2012-03-29
PT2295049E (pt) 2015-03-02
CN101257899B (zh) 2012-10-03
EP1926483B1 (en) 2010-12-01
AU2006289100A1 (en) 2007-03-15
NO20081727L (no) 2008-06-06
SI1926483T1 (sl) 2011-04-29
TNSN08103A1 (en) 2009-07-14
CA2820510A1 (en) 2007-03-15
KR101476451B1 (ko) 2014-12-24
CA2620554A1 (en) 2007-03-15
TWI376223B (en) 2012-11-11
DK2295049T3 (en) 2015-02-23
IL189665A (en) 2014-07-31
TW200803829A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
IL233328A0 (en) Treatment of autoimmune diseases
TW200509892A (en) Novel aminobenzophenone compounds
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
WO2007019080A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων
TW200628453A (en) Triazole substituted aminobenzophenone compounds
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos
MX2007003281A (es) N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central.